Bionano Genomics Registers Common Stock & Warrants on Nasdaq

TL;DR

**BNGO just confirmed its stock and warrants are properly listed on Nasdaq.**

AI Summary

Bionano Genomics, Inc. filed an 8-K on January 8, 2024, to register its Common Stock, $0.0001 par value per share, and Warrants on The Nasdaq Stock Market LLC under the trading symbol BNGO. This filing ensures the company's securities are properly listed and traded, which is crucial for investors as it maintains liquidity and visibility for their holdings. It matters to shareholders because it confirms the continued public trading of their shares and warrants.

Why It Matters

This filing confirms the continued listing and trading of Bionano Genomics' common stock and warrants on Nasdaq, ensuring market access and liquidity for investors.

Risk Assessment

Risk Level: low — This filing is a routine administrative update confirming existing listings, posing minimal risk to investors.

Analyst Insight

Investors should note this filing as a confirmation of standard compliance and continued market access for BNGO shares and warrants, indicating no immediate operational changes.

Key Numbers

• $0.0001 — Par Value per Share (The stated par value of Bionano Genomics' Common Stock.)

Key Players & Entities

• Bionano Genomics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where securities are registered
• $0.0001 (dollar_amount) — par value per share of Common Stock
• BNGO (company) — trading symbol for Common Stock

Forward-Looking Statements

• Bionano Genomics will continue to trade its Common Stock and Warrants on Nasdaq without interruption. (Bionano Genomics, Inc.) — high confidence, target: Ongoing

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq

Filing Documents

• ef20018237_8k.htm (8-K) — 28KB
• ef20018237_ex99-1.htm (EX-99.1) — 37KB
• image00001.jpg (GRAPHIC) — 2KB
• image00002.jpg (GRAPHIC) — 2KB
• image3.jpg (GRAPHIC) — 6KB
• 0001140361-24-001200.txt ( ) — 260KB
• bngo-20240108.xsd (EX-101.SCH) — 4KB
• bngo-20240108_def.xml (EX-101.DEF) — 17KB
• bngo-20240108_lab.xml (EX-101.LAB) — 26KB
• bngo-20240108_pre.xml (EX-101.PRE) — 19KB
• ef20018237_8k_htm.xml (XML) — 6KB

02

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, Bionano Genomics, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2023 and for the year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release issued January 8, 2024. 104 Inline XBRL for the cover page of this Current Report on Form 8-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 Bionano Genomics, Inc. By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR